Dr. Reddy’s Laboratories Limited (NYSE:RDY) Shares Acquired by Ashton Thomas Private Wealth LLC

Ashton Thomas Private Wealth LLC grew its stake in Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 348.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 16,729 shares of the company’s stock after purchasing an additional 13,001 shares during the quarter. Ashton Thomas Private Wealth LLC’s holdings in Dr. Reddy’s Laboratories were worth $264,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of RDY. Farther Finance Advisors LLC raised its stake in Dr. Reddy’s Laboratories by 43.2% during the third quarter. Farther Finance Advisors LLC now owns 454 shares of the company’s stock worth $36,000 after acquiring an additional 137 shares during the period. POM Investment Strategies LLC raised its stake in Dr. Reddy’s Laboratories by 400.0% during the fourth quarter. POM Investment Strategies LLC now owns 2,275 shares of the company’s stock worth $36,000 after acquiring an additional 1,820 shares during the period. Allworth Financial LP raised its stake in Dr. Reddy’s Laboratories by 447.8% during the fourth quarter. Allworth Financial LP now owns 2,728 shares of the company’s stock worth $41,000 after acquiring an additional 2,230 shares during the period. Sierra Ocean LLC acquired a new stake in Dr. Reddy’s Laboratories during the fourth quarter worth about $43,000. Finally, Independence Bank of Kentucky raised its stake in Dr. Reddy’s Laboratories by 400.0% during the fourth quarter. Independence Bank of Kentucky now owns 2,775 shares of the company’s stock worth $44,000 after acquiring an additional 2,220 shares during the period. Institutional investors and hedge funds own 3.85% of the company’s stock.

Dr. Reddy’s Laboratories Price Performance

NYSE RDY opened at $12.71 on Wednesday. Dr. Reddy’s Laboratories Limited has a 52 week low of $12.62 and a 52 week high of $16.89. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02. The stock has a market cap of $10.61 billion, a price-to-earnings ratio of 20.23 and a beta of 0.48. The company has a 50-day moving average price of $14.12 and a two-hundred day moving average price of $14.90.

Dr. Reddy’s Laboratories (NYSE:RDY) last posted its earnings results on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%. Analysts forecast that Dr. Reddy’s Laboratories Limited will post 0.8 EPS for the current year.

Analyst Upgrades and Downgrades

RDY has been the topic of several research reports. Nomura lowered shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research note on Thursday, December 19th. StockNews.com lowered shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, December 6th.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.